Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study

Peter G. Rose, James J. Java, Mark A. Morgan, Angeles Alvarez-Secord, Joshua P. Kesterson, Frederick B. Stehman, David P. Warshal, William T. Creasman, Parviz Hanjani, Robert T. Morris, Larry J. Copeland

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Purpose GOG 152 was a randomized trial of secondary cytoreductive surgery (SCS) in patients with suboptimal residual disease (residual tumor nodule > 1 cm in greatest diameter) following primary cytoreductive surgery for advanced stage ovarian cancer. The current analysis was undertaken to evaluate the impact of disease findings at SCS on progression-free survival (PFS) and overall survival (OS). Methods Among the 550 patients enrolled on GOG-152, two-hundred-sixteen patients were randomly assigned following 3 cycles of cisplatin and paclitaxel to receive SCS. In 15 patients (7%) surgery was declined or contraindicated. In the remaining 201 patients the operative and pathology reports were utilized to classify their disease status at the beginning of SCS as; no gross disease/microscopically negative N = 40 (19.9%), no gross disease/microscopically positive N = 8 (4.0%), and gross disease N = 153 (76.1%). Results The median PFS for patients with no gross disease/microscopically negative was 16.1 months, no gross disease/microscopically positive was 13.5 months and for gross disease was 11.7 months, P = 0.002. The median OS for patients with no gross disease/microscopically negative was 51.5 months, no gross disease/microscopically positive was 42.6 months and for gross disease was 34.9 months, P = 0.018. Conclusion Although as previously reported SCS did not change PFS or OS, for those who underwent the procedure, their operative and pathologic findings were predictive of PFS and OS. Surgical/pathological residual disease is a biomarker of response to chemotherapy and predictive of PFS and OS.

Original languageEnglish (US)
Pages (from-to)511-515
Number of pages5
JournalGynecologic Oncology
Volume143
Issue number3
DOIs
StatePublished - Jan 1 2016

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study'. Together they form a unique fingerprint.

  • Cite this

    Rose, P. G., Java, J. J., Morgan, M. A., Alvarez-Secord, A., Kesterson, J. P., Stehman, F. B., Warshal, D. P., Creasman, W. T., Hanjani, P., Morris, R. T., & Copeland, L. J. (2016). Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 143(3), 511-515. https://doi.org/10.1016/j.ygyno.2016.09.005